Murat Osman Arcasoy, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3912, Durham, NC 27710
Phone (919) 684-5350
Email address arcas001@mc.duke.edu

Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling

Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occuring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.

Education and Training

  • Fellow in Medical Oncology, Medicine, Yale University, 1997 - 1998
  • Hematology Fellow, Medicine, Yale University, 1992 - 1993
  • Chief Medical Resident, Medicine, State University of New York, Brooklyn, 1991 - 1992
  • Medical Resident, Medicine, State University of New York, Brooklyn, 1988 - 1991
  • M.D., Aegean University, School of Medicine (Turkey), 1987

Publications

Talpaz, Moshe, Josef Prchal, Lawrence Afrin, Murat Arcasoy, Solomon Hamburg, Jason Clark, Deanna Kornacki, Philomena Colucci, and Srdan Verstovsek. “Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.” Clin Lymphoma Myeloma Leuk 22, no. 5 (May 2022): 336–46. https://doi.org/10.1016/j.clml.2021.10.016.

PMID
34911667
Full Text

Mascarenhas, John, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, et al. “A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.” Blood 139, no. 19 (May 2022): 2931–41. https://doi.org/10.1182/blood.2021012743.

PMID
35007321
Full Text

Price, Jeremy G., Donna Niedzwiecki, Taofik Oyekunle, Murat O. Arcasoy, Colin E. Champ, Chris R. Kelsey, Joseph K. Salama, and Michael J. Moravan. “Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.” Adv Radiat Oncol 6, no. 4 (July 2021): 100729. https://doi.org/10.1016/j.adro.2021.100729.

PMID
34258474
Full Text

Oh, Stephen T., Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, et al. “ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.” Blood Adv 4, no. 18 (September 22, 2020): 4282–91. https://doi.org/10.1182/bloodadvances.2020002662.

PMID
32915978
Full Text

Gowin, Krisstina, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O. Arcasoy, Rebecca Devlin, et al. “Survival following allogeneic transplant in patients with myelofibrosis.” Blood Advances 4, no. 9 (May 2020): 1965–73. https://doi.org/10.1182/bloodadvances.2019001084.

PMID
32384540
Full Text

Mascarenhas, J., H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M. R. Baer, E. Ritchie, et al. “A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.” Leukemia 33, no. 12 (December 2019): 2974–78. https://doi.org/10.1038/s41375-019-0524-7.

PMID
31363161
Full Text

Yacoub, Abdulraheem, John Mascarenhas, Heidi Kosiorek, Josef T. Prchal, Dmitry Berenzon, Maria R. Baer, Ellen Ritchie, et al. “Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.” Blood 134, no. 18 (October 31, 2019): 1498–1509. https://doi.org/10.1182/blood.2019000428.

PMID
31515250
Full Text

Gable, Dustin L., Valeriya Gaysinskaya, Christine C. Atik, C Conover Talbot, Byunghak Kang, Susan E. Stanley, Elizabeth W. Pugh, et al. “ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.” Genes Dev 33, no. 19–20 (October 1, 2019): 1381–96. https://doi.org/10.1101/gad.326785.119.

PMID
31488579
Full Text

Grainger, Brian T., Murat O. Arcasoy, and Christopher A. Kenedi. “Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature.” Eur J Haematol 103, no. 4 (October 2019): 277–86. https://doi.org/10.1111/ejh.13285.

PMID
31257631
Full Text

Diep, Robert T., Kristin Corey, and Murat O. Arcasoy. “A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families.” Ann Hematol 98, no. 7 (July 2019): 1789–91. https://doi.org/10.1007/s00277-019-03632-y.

PMID
30747248
Full Text

Pages